

K 121917

SEP 19 2012

**9 510(K) SUMMARY**

(as required by 21 CFR 807.92)

Pursuant to Section 12, Part (a)(i)(3A) of the Safe Medical Devices Act of 1990, Penumbra Inc. is providing the summary of Substantial Equivalence for the Penumbra Embolectomy Aspiration System.

**9.1 Sponsor/Applicant Name and Address**

Penumbra, Inc.  
1351 Harbor Bay Parkway  
Alameda, CA 94502, USA

**9.2 Sponsor Contact Information**

Michaela Mahl  
Regulatory Affairs Program Manager  
Phone: (510) 748-3288  
FAX: (510) 217-6414  
Email: [michaela.mahl@penumbrainc.com](mailto:michaela.mahl@penumbrainc.com)

**9.3 Date of Preparation of 510(k) Summary**

September 14, 2012

**9.4 Device Trade or Proprietary Name**

Penumbra Embolectomy Aspiration System

**9.5 Common/Usual Name**

Penumbra Embolectomy Aspiration System

**9.6 Device Classification**

Regulatory Class: II  
Classification Panel: Cardiovascular  
Classification Name: Embolectomy catheter  
Regulation Number: 21 CFR § 870.5150  
Product Code: DXE

**9.7 Predicate Devices**

510(k) Number / Clearance Date	Name of Predicate Device	Name of Manufacturer
K100569 / 11Mar2011	Merit Embolectomy Catheter	Merit Medical Systems, Inc.
K072718 / 28Dec2007	Penumbra System	Penumbra, Inc.
K090752 / 21Sep2009	Penumbra System 054	Penumbra, Inc.
K100769 / 21May2010	Penumbra System Separator Flex [026, 032, 041, 054]	Penumbra, Inc.
K113163 / 23Nov2011	Penumbra System MAX	Penumbra, Inc.

## **9.8 Device Description**

The Penumbra Embolectomy Aspiration System's fundamental mechanism of action is aspiration. Aspiration draws the embolus or thrombus into the Aspiration Catheter to remove the embolus or thrombus from the body. All Separators function to break up the clot inside of the catheter to make it more amenable to removal from the body via aspiration. The Aspiration Catheter, Separator and Aspiration Tubing are available in multiple configurations. The devices are provided sterile, non-pyrogenic, and intended for single use only.

## **9.9 Intended Use**

The Penumbra Embolectomy Aspiration System is intended for the removal of fresh, soft emboli and thrombi from vessels of the peripheral arterial system. Not for use in the coronaries, the venous system or the neurovasculature.

## **9.10 Summary of Non-Clinical Data**

As required under Section 12, Part (a)(i)(3A) of the Safe Medical Devices Act of 1990, a summary of any information regarding safety and effectiveness of the device follows.

Included in this section are descriptions of the testing, which substantiates the safe and effective performance of the Penumbra Embolectomy Aspiration System as well as its substantial equivalence to the predicate devices:

- Biocompatibility / Pyrogenicity
- Design Verification (Bench-Top Testing)
- Animal Study

For the subject Penumbra Embolectomy Aspiration System all established requirements and acceptance criteria were met.

### **9.10.1 Biocompatibility Testing**

Biocompatibility is established for the Penumbra Embolectomy Aspiration System devices based on tests selected in accordance with EN ISO 10993 -1 guidelines (Biological Evaluation of Medical Devices) for limited duration (<24 hours), external communicating devices, contacting circulating blood. All studies were conducted pursuant to 21 CFR, Part 58, Good Laboratory Practices. In summary, non-clinical testing found the Penumbra Embolectomy Aspiration

System devices to be biocompatible according to the requirements of EN ISO 10993 requirements. In summary the following tests were performed:

Test	Method	Result
<b>Cytotoxicity</b>	L929 MEM Elution Test	Non-Toxic
<b>Sensitization</b>	Kligman Maximization	Non-Sensitizing
<b>Intracutaneous Reactivity (Irritation)</b>	Intracutaneous Injection Test	Non-Irritant
<b>Systemic Toxicity (Acute)</b>	ISO Acute Systemic Injection Test	Non-Toxic
<b>Haemocompatibility</b>	Complement Activation	No greater biological response than corresponding control
	Hemolysis	Non-Hemolytic
	Coagulation - PT	No Statistical Difference from control
	Coagulation - PTT	No Statistical Difference from control
	<i>In vivo</i> thrombogenicity	Non-Thrombogenic
<b>Pyrogenicity</b>	USP Material Mediated Rabbit Pyrogen Test	Non-Pyrogenic

#### 9.10.2 Bench-top Testing

Testing was based on the design specifications, risk analysis and available guidance documents. These guidance documents include:

- Guidance on Premarket Notification [510(k)] Submission for Short-Term and Long-Term Intravascular Catheters (FDA – 1995)
- EN ISO 10555-1:2009 - Sterile, single-use intravascular catheters – Part 1: General Requirements

Devices used for mechanical testing were assembled and packaged in the controlled production environment and sterilized twice using an ethylene oxide sterilization cycle.

The physical and mechanical properties of the Penumbra Embolectomy Aspiration System devices were assessed using standard test methods and pre-determined acceptance criteria. All established acceptance criteria were met. The following tests were performed:

- Visual & Dimensional
- Pouch Seal Strength
- Tensile Strength
- Bond Strength
- Hub Air Aspiration
- Burst Test
- Particulate Test
- Friction Test
- Flow Rate Test
- Elongation Test
- Corrosion Test
- Torsion Test
- Simulated Use
- Flexibility

The results of the tests appropriately address the physical and mechanical performance expectations of the device. This is further supported by the surgical handling and performance results reported in the in vivo study. Based on these overall results, the physical and mechanical properties of the Penumbra Embolectomy Aspiration System devices are acceptable for the intended use and substantially equivalent to the predicate devices.

#### **9.10.3 Animal Study**

Animal studies were conducted to evaluate the safe use of the Penumbra Embolectomy Aspiration System devices. The studies concluded that:

- No vessel injury was noted on the final angiograms following the vessel response procedure.
- No abnormal gross or histology findings were noted in test vessel segments.
- The use of the devices resulted in no significant vascular response in these experimental conditions.

#### **9.10.4 Summary of Substantial Equivalence**

The Penumbra Embolectomy Aspiration System is substantially equivalent to the predicate devices with regard to intended use, operating principle, design concept, materials, shelf-life, packaging and sterilization processes.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room - WO66-G609  
Silver Spring, MD 20993-0002

SEP 19 2012

Penumbra, Inc.  
c/o Michaela Mahl  
Regulatory Affairs Program Manager  
1351 Harbor Bay Parkway  
Alameda, CA 94502

Re: K121917  
Trade/Device Name: Penumbra Embolectomy Aspiration System  
Regulation Number: 21 CFR 870.5150  
Regulation Name: Embolectomy Catheter  
Regulatory Class: Class II  
Product Code: DXE  
Dated: June 29, 2012  
Received: July 2, 2012

Dear Ms. Mahl:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. However, we remind you that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Bram Zuckerman', with a long horizontal line extending to the right.

Bram Zuckerman, M.D.  
Director  
Division of Cardiovascular Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

10 Statement of Indication for Use

Indications for Use

510(k) Number (if known): K121917

Device Name: Penumbra Embolectomy Aspiration System

Indications for Use:


The Penumbra Embolectomy Aspiration System is intended for the removal of fresh, soft emboli and thrombi from vessels of the peripheral arterial system. Not for use in the coronaries, the venous system or the neurovasculature.

Prescription Use X AND/OR Over The Counter Use \_\_\_\_\_  
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
\_\_\_\_\_  
(Division Sign-Off)  
Division of Cardiovascular Devices  
510(k) Number K121917